HER2蛋白在乳腺癌靶向治疗中的作用及意义

[1] Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. G. Metro,J. Foglietta,M. Russillo,L. Stocchi,A. Vidiri,D. Giannarelli,L. Crin,P. Papaldo,M. Mottolese,F. Cognetti,A. Fabi,S. Gori. Annals of Oncology . 2011

[2] Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. Johnston Stephen,Trudeau Maureen,Kaufman Bella,Boussen Hamouda,Blackwell Kimberley,LoRusso Patricia,Lombardi Donald P,Ben Ahmed Slim,Citrin Dennis L,DeSilvio Michelle L,Harris Jennifer,Westlund Ron E,Salazar Vanessa,Zaks Tal Z,Spector Neil L. Journal of clinical oncology : official journal of the American Societ

[3] The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco Igor,Sawyers Charles L. Nature reviews. Cancer . 2002

[4] PC Cell?Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells. Wes E. Kim,Ginette Serre. Clinical Cancer Research . 2006

[5] Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN,FOXO,phosphorylated Stat5,and autophagy protein signaling. Holmes FA,Espina V,Liotta LA,et al. BMC Res Notes . 2013

[6] Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women:Review of the Anatolian Society of Medical Oncology (ASMO)Experience. Cetin B,Benekli M,Dane F,et al. Breast Care . 2013

[7] Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Price-Schiavi Shari A,Jepson Scott,Li Peter,Arango Maria,Rudland Philip S,Yee Lisa,Carraway Kermit L. International journal of cancer. Journal international du cancer . 2002

[8] Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). Yuhong Lu,Xiaolin Zi,Yunhua Zhao,Desmond Mascarenhas,Michael Poll. Journal of the National Cancer Institute . 2001

[9] Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Xia Wenle,Liu Lei-Hua,Ho Peter,Spector Neil L. Oncegene . 2004

[10] Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Nagy Peter,Friedl?nder Elza,Tanner Minna,Kapanen Anita I,Carraway Kermit L,Isola Jorma,Jovin Thomas M. Cancer Research . 2005

[1] Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. G. Metro,J. Foglietta,M. Russillo,L. Stocchi,A. Vidiri,D. Giannarelli,L. Crin,P. Papaldo,M. Mottolese,F. Cognetti,A. Fabi,S. Gori. Annals of Oncology . 2011

[2] Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. Johnston Stephen,Trudeau Maureen,Kaufman Bella,Boussen Hamouda,Blackwell Kimberley,LoRusso Patricia,Lombardi Donald P,Ben Ahmed Slim,Citrin Dennis L,DeSilvio Michelle L,Harris Jennifer,Westlund Ron E,Salazar Vanessa,Zaks Tal Z,Spector Neil L. Journal of clinical oncology : official journal of the American Societ

[3] The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco Igor,Sawyers Charles L. Nature reviews. Cancer . 2002

[4] PC Cell?Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells. Wes E. Kim,Ginette Serre. Clinical Cancer Research . 2006

[5] Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN,FOXO,phosphorylated Stat5,and autophagy protein signaling. Holmes FA,Espina V,Liotta LA,et al. BMC Res Notes . 2013

[6] Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women:Review of the Anatolian Society of Medical Oncology (ASMO)Experience. Cetin B,Benekli M,Dane F,et al. Breast Care . 2013

[7] Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Price-Schiavi Shari A,Jepson Scott,Li Peter,Arango Maria,Rudland Philip S,Yee Lisa,Carraway Kermit L. International journal of cancer. Journal international du cancer . 2002

[8] Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). Yuhong Lu,Xiaolin Zi,Yunhua Zhao,Desmond Mascarenhas,Michael Poll. Journal of the National Cancer Institute . 2001

[9] Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Xia Wenle,Liu Lei-Hua,Ho Peter,Spector Neil L. Oncegene . 2004

[10] Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Nagy Peter,Friedl?nder Elza,Tanner Minna,Kapanen Anita I,Carraway Kermit L,Isola Jorma,Jovin Thomas M. Cancer Research . 2005